Compound controlled-release preparation containing topiroxostat

A controlled-release preparation, the technology of topiramast, is applied in the directions of medical preparations containing active ingredients, medical preparations without active ingredients, pharmaceutical formulas, etc., and can solve the problems of obvious side effects and the like

A controlled-release preparation, the technology of topiramast, is applied in the directions of medical preparations containing active ingredients, medical preparations without active ingredients, pharmaceutical formulas, etc., and can solve the problems of obvious side effects and the like

CN110974823AInactive Publication Date: 2020-04-10CP PHARMA QINGDAO CO LTD
0 Cites 0 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound controlled-release preparation containing topiroxostat
  • Compound controlled-release preparation containing topiroxostat

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Prescription 1 (according to 1000 capsules)

[0012] A. Topirast immediate-release granules

[0013] Topirast 5g

[0014] Microcrystalline Cellulose 2.85g

[0015] Low-substituted hydroxypropyl cellulose 6.0g

[0016] Crospovidone 0.9g

[0017] Lactose 3.0g

[0018] Magnesium stearate 0.15g

[0019] B. Topirast controlled-release granules

[0020] Topirast 15g

[0021] Microcrystalline Cellulose 8.5g

[0022] Low-substituted hydroxypropyl cellulose 7.8g

[0023] Croscarmellose 10g

[0024] Lactose 9.0g

[0025] Magnesium Stearate 4.0g

[0026] C. Febuxostat controlled-release granules

[0027] Febuxostat 40g

[0028] Hydroxypropyl Methyl Cellulose 38g

[0029] Ethylcellulose 6.0g

[0030] Lactose 6.0g

[0031] Magnesium Stearate 0.3g.

[0032] Preparation method:

[0033] (1) Topiralast and febuxostat are pulverized through an 80 mesh sieve;

[0034] (2) Mix the controlled-release material evenly, and pulverize through a 120-mesh sieve;

[0035] (3) ...

Embodiment 2

[0039] Prescription 2 (according to 1000 capsules)

[0040] A. Topirast immediate-release granules

[0041] Topirast 5g

[0042] Microcrystalline Cellulose 2.85g

[0043] Low-substituted hydroxypropyl cellulose 6.0g

[0044] Crospovidone 0.9g

[0045] Lactose 3.0g

[0046] Magnesium stearate 0.15g

[0047] B. Topirast controlled-release granules

[0048] Topirast 15g

[0049] Microcrystalline Cellulose 10.5g

[0050] Low-substituted hydroxypropyl cellulose 8.5g

[0051] Croscarmellose 12g

[0052] Lactose 8.0g

[0053] Magnesium Stearate 4.0g

[0054] C. Febuxostat controlled-release granules

[0055] Febuxostat 40g

[0056] Hydroxypropyl Methyl Cellulose 45g

[0057] Ethylcellulose 8.0g

[0058] Lactose 4.0g

[0059] Magnesium Stearate 0.3g.

[0060] Preparation method is the same as embodiment 1.

Embodiment 3

[0062] Prescription 3 (according to 1000 capsules)

[0063] A. Topirast immediate-release granules

[0064] Topirast 5g

[0065] Microcrystalline Cellulose 2.85g

[0066] Low-substituted hydroxypropyl cellulose 6.0g

[0067] Crospovidone 0.9g

[0068] Lactose 3.0g

[0069] Magnesium stearate 0.15g

[0070] B. Topirast controlled-release granules

[0071] Topirast 15g

[0072] Microcrystalline Cellulose 8.5g

[0073] Low-substituted hydroxypropyl cellulose 9.5g

[0074] Croscarmellose 10g

[0075] Lactose 9.0g

[0076] Magnesium Stearate 4.5g

[0077] C. Febuxostat controlled-release granules

[0078] Febuxostat 40g

[0079] Hydroxypropyl Methyl Cellulose 35g

[0080]Ethylcellulose 6.0g

[0081] Lactose 8.0g

[0082] Magnesium Stearate 0.25g.

[0083] Preparation method is the same as embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of pharmaceutical preparations, and in particular relates to a compound drug controlled-release preparation containing topiroxostat and febuxostat. The invention also discloses a preparation method of the compound drug controlled-release preparation containing topiramate and febuxostat. Compared with the prior art, the compound drug controlled-release preparationprovided by the invention can release a drug slowly at a constant speed in a prescribed release medium, so that the release rate and bioavailability of the compound drug controlled-release preparation are effectively improved, the preparation can be rapidly released in the early stage of medication to produce drug effects and can be slowly released at a constant speed in the later stage to maintain a normal blood drug concentration, and the preparation maintains the drug effects for a long time without producing toxic and side effects or causing drug accumulation and poisoning, improves the efficacy, and is safe and quick; and at the same time, the preparation method provided by the invention is suitable for scale-up production.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a compound controlled-release preparation containing topiramate, which belongs to the technical field of medicine. Background technique [0002] Uric acid is a normal product of purine nucleotide metabolism. When uric acid is produced excessively and uric acid excretion decreases, hyperuricemia is formed when the uric acid in the blood rises beyond the normal range; excessive uric acid in the blood is mainly deposited in the joints, cartilage, Subcutaneous soft tissue and kidneys cause comprehensive clinical manifestations such as arthritis and kidney disease, which is called gout. Therefore, hyperuricemia and uric acid deposition in organ tissues are the basic pathogenesis of gout. The etiology leading to elevated uric acid is more complex and can be divided into two categories: primary and secondary. [0003] With the improvement of people's living standards, improve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
10 Apr 2020
Publication
CN110974823A
IPC
A61K31/426; A61K31/444; A61K9/52; A61K47/38; A61P19/06
CPC
A61K9/5042; A61K9/5047; A61K31/426; A61K31/444; A61P19/06; A61K2300/00
Inventors
陈阳生; 王明刚